Table 2 Multiple regression analysis of factors associated with the levels of IFN-γ induced by Ag1 and Ag2 responses 6 months after administration of the BNT162b2 vaccine.

Ag1

Age

1.015

1.000

1.030

0.0473

 Sex (female)

0.788

0.571

1.086

0.1451

 Na (mEq/L, pre)

1.042

0.948

1.145

0.3898

 Cl (mEq/L, pre)

1.056

0.976

1.142

0.1744

 Triglyceride (mg/dL, post 1st dose)

0.999

0.998

1.001

0.3310

 Activated partial thromboplastin time (s, post 1st dose)

0.966

0.919

1.015

0.1725

 Anti-spike IgG (AU/mL, post 2nd dose)

1.000

1.000

1.000

0.6152

 Drinking (daily)

1.292

0.935

1.786

0.1201

 Comorbidity (dyslipidemia)

0.736

0.380

1.426

0.3625

 Focal adverse reactions only (post 2nd dose)

0.739

0.524

1.041

0.0835

 Neutrophils (every 100/μL, post 1st dose)

0.999

0.987

1.011

0.8294

 Basophils (every 100/μL, post 1st dose)

0.590

0.338

1.030

0.0633

 Ag1 (3 weeks after 1st dose)

1.366

1.213

1.537

 < 0.0001

 Ag1 (3 weeks after 2nd dose)

1.130

1.065

1.200

0.0001

Ag2

 Age

1.016

1.003

1.030

0.0176

 Sex (female)

0.850

0.583

1.239

0.3967

 Na (mEq/L, post 1st dose)

0.979

0.893

1.074

0.6582

 Cl (mEq/L, post 1st dose)

1.033

0.958

1.115

0.3943

 Hemoglobin (g/dL, post 1st dose)

1.084

0.953

1.233

0.2168

 Platelet (× 10⁴/μL, post 1st dose)

1.009

0.984

1.035

0.4789

 IgG Titer (AU/mL, post 2nd dose)

1.000

1.000

1.000

0.9206

 Comorbidity (dyslipidemia)

0.532

0.292

0.969

0.0393

 Focal adverse reactions only (post 2nd dose)

0.680

0.492

0.940

0.0198

 Neutrophils (every 100/μL, post 1st dose)

0.999

0.987

1.011

0.8602

 Lymphocytes (every 100/μL, post 1st dose)

1.036

1.008

1.065

0.0115

 Monocytes (every 100/μL, post 1st dose)

0.821

0.706

0.954

0.0101

 Basophil (every 100/μL, post 1st dose)

0.677

0.390

1.174

0.1643

 Ag2 (3 weeks after 1st dose)

1.315

1.190

1.454

 < 0.0001

 Ag2 (3 weeks after 2nd dose)

1.071

1.038

1.105

 < 0.0001